Oryzon Genomics Balance Sheet Health
Financial Health criteria checks 4/6
Oryzon Genomics has a total shareholder equity of $85.7M and total debt of $21.3M, which brings its debt-to-equity ratio to 24.8%. Its total assets and total liabilities are $114.2M and $28.5M respectively.
Key information
24.8%
Debt to equity ratio
US$21.29m
Debt
Interest coverage ratio | n/a |
Cash | US$14.65m |
Equity | US$85.70m |
Total liabilities | US$28.48m |
Total assets | US$114.18m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ORN's short term assets ($20.3M) exceed its short term liabilities ($16.8M).
Long Term Liabilities: ORN's short term assets ($20.3M) exceed its long term liabilities ($11.7M).
Debt to Equity History and Analysis
Debt Level: ORN's net debt to equity ratio (7.7%) is considered satisfactory.
Reducing Debt: ORN's debt to equity ratio has reduced from 58% to 24.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ORN has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ORN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.